SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1690)1/29/1999 2:59:00 PM
From: j_fir2  Read Replies (1) | Respond to of 10280
 
Any possibility it's also just that the public recognition of Sepracor has reached a critical mass? Bloomberg, Worth...often in association with big pharm Eli Lilly...and the perception of a potential geometric increase in the value of the company's stock, since they are building on others' successes.

Time will tell.
j'fir



To: Biomaven who wrote (1690)1/29/1999 5:00:00 PM
From: Andreas Helke  Read Replies (1) | Respond to of 10280
 
There is one important difference between Agouron and Sepracor. Agouron is profitable and it actually has a considerably lower price/sales ratio then WLA. Sepracor will have a bright future but the combination of high market cap and heavy losses will make it a target that is difficult to digest. Sepracors losses will be very bad for the income statement and possibly the stock price of the acquiring company.

Andreas


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News